

Irit Avivi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1755416/publications.pdf>

Version: 2024-02-01

172
papers

7,935
citations

172457
29
h-index

54911
84
g-index

178
all docs

178
docs citations

178
times ranked

10676
citing authors

#	ARTICLE	IF	CITATIONS
1	Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients â€” a matched control multicenter cohort study. <i>Haematologica</i> , 2022, 107, 1111-1118.	3.5	25
2	[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 953-962.	6.4	27
3	Characteristics and recognition of early infections in patients treated with commercial antiâ€”CD19 CARâ€”T cells. <i>European Journal of Haematology</i> , 2022, 108, 52-60.	2.2	10
4	Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 148-151.	5.2	15
5	BNT162b2 mRNA COVIDâ€”19 vaccine booster induces seroconversion in patients with Bâ€”cell nonâ€”Hodgkin lymphoma who failed to respond to two prior vaccine doses. <i>British Journal of Haematology</i> , 2022, 196, 1329-1333.	2.5	13
6	Is There a Role for [18F]FDG PET-CT in Staging MALT Lymphoma?. <i>Cancers</i> , 2022, 14, 750.	3.7	5
7	Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCLâ€”a matched cohort analysis. <i>Annals of Hematology</i> , 2022, 101, 755.	1.8	1
8	The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients. <i>Clinical Microbiology and Infection</i> , 2022, 28, 735.e5-735.e8.	6.0	12
9	REGENâ€”COV antibody combination in patients with lymphoproliferative malignancies and SARSâ€”CoVâ€”2 infection. <i>EJHaem</i> , 2022, 3, 471-474.	1.0	4
10	Monoclonal gammopathy of renal significance (MGRS): Realâ€”world data on outcomes and prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, 877-884.	4.1	12
11	COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge. <i>Cancer Cell</i> , 2022, 40, 578-580.	16.8	12
12	Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. <i>Blood</i> , 2022, 140, 2248-2260.	1.4	20
13	Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 118-124.	1.3	23
14	Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative diseaseâ€”a single center case series. <i>Bone Marrow Transplantation</i> , 2021, 56, 1031-1037.	2.4	25
15	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. <i>Translational Oncology</i> , 2021, 14, 100977.	3.7	13
16	Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients. <i>Journal of Neuro-Oncology</i> , 2021, 151, 211-220.	2.9	5
17	Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma. <i>British Journal of Haematology</i> , 2021, 192, e1-e4.	2.5	4
18	Daratumumab for relapsed AL amyloidosisâ€”When cumulative realâ€”world data precedes clinical trials: A multisite study and systematic literature review. <i>European Journal of Haematology</i> , 2021, 106, 184-195.	2.2	14

#	ARTICLE	IF	CITATIONS
19	Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy. British Journal of Haematology, 2021, 193, 52-62.	2.5	14
20	Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study. Therapeutic Advances in Hematology, 2021, 12, 204062072110352.	2.5	11
21	Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study. Leukemia Research, 2021, 101, 106498.	0.8	1
22	Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nature Medicine, 2021, 27, 491-503.	30.7	118
23	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood, 2021, 137, 3165-3173.	1.4	539
24	Lower Patient Anxiety and Unchanged Levels of Adherence to Hemato-Oncologic Treatment in Response to New Measures to Reduce Hospital Exposure Risk to COVID-19. Patient Preference and Adherence, 2021, Volume 15, 945-952.	1.8	2
25	Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3540-3549.	6.4	33
26	Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells. Frontiers in Oncology, 2021, 11, 646971.	2.8	7
27	Diabetes, but not pre-diabetes, is associated with shorter time to second-line therapy and worse outcomes in patients with multiple myeloma. Leukemia and Lymphoma, 2021, 62, 2785-2792.	1.3	2
28	Peripheral B cells repress B-cell regeneration in aging through a TNF- α /IGFBP-1/IGF-1 immune-endocrine axis. Blood, 2021, 138, 1817-1829.	1.4	17
29	Feasibility of CD24/CD11b as a Screening Test for Hematological Malignancies. Journal of Personalized Medicine, 2021, 11, 724.	2.5	4
30	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. British Journal of Haematology, 2021, 194, 690-700.	2.5	88
31	Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. British Journal of Haematology, 2021, 195, 186-193.	2.5	65
32	Predictors of Early and Late Mortality for Patients with Hematologic Malignancy and Invasive Mold Disease. Journal of Fungi (Basel, Switzerland), 2021, 7, 697.	3.5	1
33	Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy: A Single-Center Prospective Cohort Study. Transplantation and Cellular Therapy, 2021, 27, 788-794.	1.2	125
34	Extracellular Vesicles Derived from Chimeric Antigen Receptor-T Cells: A Potential Therapy for Cancer. Human Gene Therapy, 2021, 32, 1224-1241.	2.7	24
35	Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. British Journal of Haematology, 2021, 195, 388-398.	2.5	47
36	Evaluation of Scpio Labs X100 Full Field PBS: The first high-resolution full field viewing of peripheral blood specimens combined with artificial intelligence-based morphological analysis. International Journal of Laboratory Hematology, 2021, 43, 1408-1416.	1.3	19

#	ARTICLE	IF	CITATIONS
37	Low FXIII activity levels in intensive care unit hospitalized COVID-19 patients. <i>Thrombosis Journal</i> , 2021, 19, 79.	2.1	8
38	Automated Digital Morphometry of Peripheral Blood Smears Detects Both Infrequent Events and Cellular Population Patterns in Myelodysplastic Syndrome. <i>Blood</i> , 2021, 138, 3999-3999.	1.4	0
39	Sequential Therapy with Fitcy Preparative Regimen for Patients with Primary Refractory AML - a Single Center Retrospective Analysis. <i>Blood</i> , 2021, 138, 2860-2860.	1.4	0
40	Multiple Myeloma Oligosecretory Relapse, a Non-Negligible Phenomenon. Frequency, Clinical Characteristics and Outcomes in a Single Center. <i>Blood</i> , 2021, 138, 3772-3772.	1.4	1
41	Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 2606-2606.	1.4	3
42	Performance Evaluation Study of a Novel Digital Microscopy System for the Quantitative Analysis of Bone Marrow Aspirates. <i>Blood</i> , 2021, 138, 4000-4000.	1.4	1
43	Using Machine Learning Methods to Explore the Role of Non-Coding RNAs in DLBCL. <i>Blood</i> , 2021, 138, 4324-4324.	1.4	1
44	Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban. <i>Acta Haematologica</i> , 2020, 143, 266-271.	1.4	8
45	Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity. <i>Cancer Immunology Research</i> , 2020, 8, 1485-1495.	3.4	19
46	The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data. <i>Leukemia Research</i> , 2020, 97, 106429.	0.8	2
47	Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e850-e857.	0.4	1
48	Characteristics and outcomes of adults with cytomegalovirus-associated thrombocytopenia: a case series and literature review. <i>British Journal of Haematology</i> , 2020, 191, 863-867.	2.5	10
49	Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 489.	2.6	3
50	Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study. <i>Annals of Hematology</i> , 2020, 99, 1273-1281.	1.8	16
51	The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants. <i>British Journal of Haematology</i> , 2020, 189, e31-e33.	2.5	9
52	Bortezomib washout duration prior to stem cell mobilization in patients with newly diagnosed multiple myeloma. <i>European Journal of Haematology</i> , 2020, 105, 30-34.	2.2	2
53	Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen. <i>Leukemia and Lymphoma</i> , 2020, 61, 2638-2644.	1.3	2
54	Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group. <i>American Journal of Hematology</i> , 2020, 95, 465-471.	4.1	9

#	ARTICLE	IF	CITATIONS
55	Kinetics of <sc>preâ€myelodysplastic</sc> syndromes blood values correlate with disease risk and survival. Hematological Oncology, 2020, 38, 782-791.	1.7	1
56	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. American Journal of Hematology, 2020, 95, 503-509.	4.1	11
57	Discovery of tumoricidal DNA oligonucleotides by response-directed inÂvitro evolution. Communications Biology, 2020, 3, 29.	4.4	1
58	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. Annals of Hematology, 2020, 99, 1251-1255.	1.8	17
59	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1885-1893.	1.3	3
60	Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.. Journal of Clinical Oncology, 2020, 38, 8012-8012.	1.6	10
61	A Novel Approach to Blood Smear Analysis Based on Specimen Topology: Implications for Human and Artificial Intelligence Decision Making. Blood, 2020, 136, 8-9.	1.4	0
62	A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial. Blood, 2020, 136, 19-20.	1.4	0
63	Hematological malignancies during pregnancy (Review). Molecular and Clinical Oncology, 2019, 10, 3-9.	1.0	4
64	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leukemia and Lymphoma, 2019, 60, 118-123.	1.3	23
65	Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naïve multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2019, 6, e448-e458.	4.6	168
66	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2019, 6, e459-e469.	4.6	174
67	Hematogenous extramedullary relapse in multiple myeloma â€a multicenter retrospective study in 127 patients. American Journal of Hematology, 2019, 94, 1132-1140.	4.1	24
68	Romidepsin treatment for relapsed or refractory peripheral and cutaneous Tâ€cell lymphoma: Realâ€life data from a national multicenter observational study. Hematological Oncology, 2019, 37, 569-577.	1.7	17
69	Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. Lancet Haematology,the, 2019, 6, e551-e561.	4.6	45
70	Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study. American Journal of Hematology, 2019, 94, 992-1001.	4.1	14
71	Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agentsâ€a multicenter historical prospective study. Annals of Hematology, 2019, 98, 1927-1932.	1.8	56
72	Depletion of B cells rejuvenates the peripheral Bâ€cell compartment but is insufficient to restore immune competence in aging. Aging Cell, 2019, 18, e12959.	6.7	19

#	ARTICLE	IF	CITATIONS
73	Current treatment of lymphoma in pregnancy. Expert Review of Hematology, 2019, 12, 449-459.	2.2	11
74	Characteristics and outcomes of young adults with Philadelphiaâ€negative myeloproliferative neoplasms. European Journal of Haematology, 2019, 102, 504-508.	2.2	13
75	Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. Haematologica, 2019, 104, 1798-1803.	3.5	10
76	Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy. Molecular Cancer Research, 2019, 17, 2331-2340.	3.4	21
77	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Lancet Haematology, the, 2019, 6, e67-e78.	4.6	146
78	Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data. Blood, 2019, 134, 5321-5321.	1.4	3
79	Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma. Blood, 2019, 134, 243-243.	1.4	42
80	Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study. Blood, 2019, 134, 3180-3180.	1.4	0
81	Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study. Blood, 2019, 134, 5654-5654.	1.4	0
82	Is the Achievement of Pre-Autologous Transplant CR Necessary Indeed in Refractory/ Relapsed DLBCL Patients? a Retrospective Multicenter Study. Blood, 2019, 134, 5703-5703.	1.4	0
83	Personalized Ubiquitination Signatures for Predicting Response to Proteasome Inhibitor-Based Therapy of MM Patients. Blood, 2019, 134, 3371-3371.	1.4	0
84	Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2018, 53, 1001-1009.	2.4	23
85	Primary plasma cell leukemia in the era of novel agents for myeloma â€ a multicenter retrospective analysis of outcome. Leukemia Research, 2018, 68, 9-14.	0.8	14
86	Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation. Cancer Immunology, Immunotherapy, 2018, 67, 739-748.	4.2	9
87	Community-acquired respiratory infections are common in patients with non-Hodgkin lymphoma and multiple myeloma. Supportive Care in Cancer, 2018, 26, 2425-2431.	2.2	6
88	Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy â€ a case series and review of the literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 11-17.	3.0	6
89	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. British Journal of Haematology, 2018, 180, 831-839.	2.5	41
90	Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study. Annals of Hematology, 2018, 97, 459-466.	1.8	1

#	ARTICLE	IF	CITATIONS
91	Extended vs Bolus Infusion of Broad-Spectrum β -Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial. <i>Clinical Infectious Diseases</i> , 2018, 67, 1153-1160.	5.8	38
92	Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2018, 59, 610-616.	1.3	24
93	Treatment and prognosis of stage I follicular lymphoma in the modern era – does PET matter?. <i>Leukemia and Lymphoma</i> , 2018, 59, 1163-1171.	1.3	3
94	CT findings are highly predictive for perforation in patients with diffuse large B-cell lymphoma involving the intestines. <i>Leukemia and Lymphoma</i> , 2018, 59, 1878-1883.	1.3	1
95	Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. <i>Nature Medicine</i> , 2018, 24, 1867-1876.	30.7	179
96	Ten Things to Know About Primary Mediastinal B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1959-1960.	2.0	0
97	Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center. <i>Acta Haematologica</i> , 2018, 140, 194-202.	1.4	4
98	Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?. <i>European Journal of Haematology</i> , 2018, 101, 502-507.	2.2	6
99	Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study. <i>American Journal of Hematology</i> , 2018, 93, E238-E241.	4.1	6
100	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. <i>British Journal of Haematology</i> , 2018, 182, 807-815.	2.5	19
101	Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease: Portrait of a rare clinical entity. <i>Leukemia Research</i> , 2018, 71, 1-5.	0.8	14
102	Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group. <i>Blood</i> , 2018, 132, 3295-3295.	1.4	1
103	Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study. <i>Blood</i> , 2018, 132, 1972-1972.	1.4	1
104	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. <i>Blood</i> , 2018, 132, 4452-4452.	1.4	3
105	Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience. <i>Blood</i> , 2018, 132, 3259-3259.	1.4	3
106	A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8021-8021.	1.6	19
107	Single cell analysis of multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8026-8026.	1.6	1
108	Prothrombin Complex Concentrate Is Safe and Effective for Achieving Hemostasis in the Setting of Urgent Surgery for Patients Treated with Direct Xa Inhibitors. <i>Blood</i> , 2018, 132, 2541-2541.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. <i>Blood</i> , 2018, 132, 2004-2004.	1.4	1
110	Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study. <i>Annals of Hematology</i> , 2017, 96, 271-278.	1.8	9
111	Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantationâ€”a retrospective national multicenter study. <i>Annals of Hematology</i> , 2017, 96, 575-579.	1.8	5
112	Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, 874-882.	3.5	67
113	Familial chronic lymphocytic leukemia in Israel: A disproportionate distribution among Ashkenazi Jews. <i>European Journal of Haematology</i> , 2017, 99, 51-55.	2.2	0
114	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	2.5	45
115	Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone. <i>Annals of Hematology</i> , 2017, 96, 461-467.	1.8	7
116	Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. <i>Haematologica</i> , 2017, 102, 1913-1922.	3.5	52
117	The management of hodgkin lymphomas in pregnancies. <i>European Journal of Haematology</i> , 2017, 99, 385-391.	2.2	18
118	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	27.0	3,865
119	Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. <i>Hematological Oncology</i> , 2017, 35, 734-740.	1.7	6
120	Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. <i>Blood</i> , 2017, 130, 833-833.	1.4	12
121	Host Factors Affect the Clinical Presentation and Biomarker Sensitivity in Patients with Invasive Pulmonary Aspergillosis. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
122	Does molecular analysis increase the efficacy of bronchoalveolar lavage in the diagnosis and management of respiratory infections in hemato-oncological patients?. <i>International Journal of Infectious Diseases</i> , 2016, 50, 48-53.	3.3	12
123	Characteristics and outcomes of patients with multiple myeloma aged 21â€”40Âyears versus 41â€”60Âyears: a multiâ€”institutional caseâ€”control study. <i>British Journal of Haematology</i> , 2016, 175, 884-891.	2.5	21
124	Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. <i>British Journal of Haematology</i> , 2016, 172, 89-96.	2.5	33
125	Polymicrobial pulmonary infection in patients with hematological malignancies: prevalence, co-pathogens, course and outcome. <i>Infection</i> , 2016, 44, 491-497.	4.7	40
126	Reduced-dose ICE chemotherapyâ€”rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1633-1639.	1.3	12

#	ARTICLE	IF	CITATIONS
127	Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2016, 34, 501-508.	1.6	78
128	Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance. <i>Leukemia and Lymphoma</i> , 2016, 57, 1382-1388.	1.3	10
129	Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. <i>Leukemia and Lymphoma</i> , 2016, 57, 63-69.	1.3	25
130	TLR9-Regulated IL10 Mediates Immune Inhibitory Activity of Chronic Lymphocytic Leukemia B-Cells. <i>Blood</i> , 2016, 128, 4377-4377.	1.4	1
131	Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series. <i>Blood</i> , 2016, 128, 5699-5699.	1.4	1
132	Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1. <i>Blood</i> , 2016, 128, LBA-6-LBA-6.	1.4	30
133	Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma. <i>Israel Medical Association Journal</i> , 2016, 18, 411-417.	0.1	2
134	Impaired migration capacity in monocytes derived from patients with Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 55, 180-186.	1.4	11
135	Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice. <i>Clinical Cancer Research</i> , 2015, 21, 3853-3861.	7.0	20
136	Management of Hematologic Malignancies: Special Considerations in Pregnant Women. <i>Drugs</i> , 2015, 75, 1725-1738.	10.9	68
137	Respiratory Infections and Activity of Anti-Flu Vaccine in Patients with Lymphoma and Multiple Myeloma. <i>Blood</i> , 2015, 126, 4617-4617.	1.4	0
138	Different Sources of Stromal Cells Diversely Affect Survival and Trafficking of Mantle Cell Lymphoma Cells. <i>Blood</i> , 2015, 126, 2670-2670.	1.4	0
139	Dendritic Cell Cancer Vaccines: From the Bench to the Bedside. <i>Rambam Maimonides Medical Journal</i> , 2014, 5, e0024.	1.0	11
140	Management of acute myeloid leukemia during pregnancy. <i>Future Oncology</i> , 2014, 10, 1407-1415.	2.4	10
141	Development of multifocal leukoencephalopathy in patients undergoing allogeneic stem cell transplantation – can preemptive detection of John Cunningham virus be useful?. <i>International Journal of Infectious Diseases</i> , 2014, 26, 107-109.	3.3	13
142	Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1782-1791.	1.6	84
143	Non-Hodgkin lymphomas in pregnancy: Tackling therapeutic quandaries. <i>Blood Reviews</i> , 2014, 28, 213-220.	5.7	18
144	Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy. <i>Blood</i> , 2014, 124, 4471-4471.	1.4	19

#	ARTICLE	IF	CITATIONS
145	Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL). Blood, 2014, 124, 78-78.	1.4	23
146	BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial. Blood, 2014, 124, 950-950.	1.4	11
147	Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study. Blood, 2014, 124, 3488-3488.	1.4	0
148	Autologous Stem Cell Transplantation for Primary Mediastinal B Cell Lymphoma in the Rituximab Era: A Retrospective Study By the EBMT Lymphoma Working Party. Blood, 2014, 124, 1195-1195.	1.4	2
149	Elevated Involved Light Chains Discordant to the Increase of the Involved Heavy Chains Identifies a Subset of Multiple Myeloma Patients with Worse Outcome. Blood, 2014, 124, 2132-2132.	1.4	0
150	Efficacy and Safety of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Multiple Myeloma: A Retrospective Israeli Multi-Site Cohort Study. Blood, 2014, 124, 3989-3989.	1.4	0
151	High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study. Blood, 2014, 124, 2526-2526.	1.4	2
152	Busulfan Fludarabine Vs. Busulfan Cyclophosphamide As a Preparative Regimen Prior to Allogeneic Hematopoietic Cell Transplantation – Systematic Review and Meta-analysis. Blood, 2014, 124, 3872-3872.	1.4	2
153	Anti-CD20 monoclonal antibodies: Beyond B-cells. Blood Reviews, 2013, 27, 217-223.	5.7	55
154	A subset of CD8+ T cells acquiring selective suppressive properties may play a role in GvHD management. Transplant Immunology, 2013, 28, 57-61.	1.2	11
155	Strikingly high false positivity of surveillance FDG PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. American Journal of Hematology, 2013, 88, 400-405.	4.1	78
156	Acute Myeloid Leukemia Diagnosed During Pregnancy: Facing Challenges. Systematic Review and Analysis Of 174 Reported Cases. Blood, 2013, 122, 1421-1421.	1.4	3
157	Integration Of CT-Based Measurements Into PET Assessment Significantly Improves The Positive Predictive Value Of Surveillance FDG PET/CT In Patients With Diffuse Large B Cell Lymphoma. Blood, 2013, 122, 4296-4296.	1.4	0
158	High-Dose Cyclophosphamide In Combination With G-CSF Versus G-CSF Alone For Mobilization Of Hematopoietic Stem Cells After Induction Therapy Including Velcade, Cyclophosphamide and Dexacort. Blood, 2013, 122, 5369-5369.	1.4	0
159	Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors. Annals of Hematology, 2012, 91, 215-221.	1.8	15
160	Final Results of the BP22333 Study Demonstrate Non-Inferior Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Administration of Rituximab Compared with Intravenous (IV) Administration As Maintenance Therapy in Patients with Follicular Lymphoma (FL). Blood, 2012, 120, 1641-1641.	1.4	9
161	Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 –EMERGE–Study. Blood, 2012, 120, 905-905.	1.4	18
162	Absolute Monocyte Count At Diagnosis Is a Poor Prognostic Factor and Impacts Survival in Diffuse Large B-Cell Lymphoma: A Collaborative Multi-Center Study Involving 1026 Patients.. Blood, 2012, 120, 2651-2651.	1.4	0

#	ARTICLE	IF	CITATIONS
163	¹⁸ F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients. Journal of Nuclear Medicine, 2010, 51, 25-30.	5.0	352
164	Not All Positive Interim PET/CT Scans Are Reliably Predictive for Progression Free Survival in Hodgkin Lymphoma (HL) Patients. A Proposed Model for a Functional Scoring Scale.. Blood, 2008, 112, 1452-1452.	1.4	1
165	Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma. Blood, 2008, 112, 826-826.	1.4	1
166	Induced CD4+CD25+ FOXP-3+ and CD8+CD25+ FOXP-3+t Cells Exhibit a Concurrent Expression of Effector and Selective Suppressive Capacities. Blood, 2008, 112, 3501-3501.	1.4	0
167	Allogeneic Stem Cell Transplantation (ASCT) in CML with Partial T-Cell Depletion, No Prophylaxis for Graft-Versus-Host Disease (GvHD) and Preemptive DLI for Patients with Post-Transplant Minimal Residual Disease (MRD): An Alternative Approach in CML Transplantation with Low Morbidity and Long Term Disease Free Survival.. Blood, 2006, 108, 318-318.	1.4	1
168	Prognostic factors in acute myeloid leukemia. Current Opinion in Hematology, 2005, 12, 62-67.	2.5	33
169	Conventional allograft and autograft in low grade lymphoma. Best Practice and Research in Clinical Haematology, 2005, 18, 113-128.	1.7	3
170	Use of Dendritic Cells Versus Peripheral Blood Lymphocytes To Segregate Alloreactive and Regulatory T Cells during Allogeneic Transplantation.. Blood, 2005, 106, 5244-5244.	1.4	0
171	CA-125 as a Marker for the Early Diagnosis of Hepatic Veno-Occlusive Disease Following Hematopoietic Stem Cell Transplantation.. Blood, 2004, 104, 1138-1138.	1.4	0
172	Lymphoproliferative disease detected by breast cancer screening. Journal of Medical Screening, 0, , 096914132211099.	2.3	0